Health Care • Biotechnology: Electromedical & Electrotherapeutic Apparatus
$6.94 ▼ -0.12
(-1.70%)
MKT CAP: $369.2M • VOL: 102.0K
52W L $5 52W H $15
CV // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 |
|---|---|---|
| Revenue (Total Sales) | $13.6M | $11.8M |
| YoY Revenue Growth % | +15.3% | — |
| Gross Profit | $7.2M | $6.4M |
| Gross Margin % | 52.9% | 54.2% |
| Research & Development (R&D) | — | — |
| Operating Income (EBIT) | -$25.5M | -$19.9M |
| Operating Margin % | -80.0% | -80.0% |
| Net Income (GAAP) | -$25.3M | -$19.9M |
| EBITDA (Normalized) | -$25.4M | -$19.8M |
| Diluted EPS ($/sh) | — | — |
| Operating Cash Flow (OCF) | -$22.9M | -$20.1M |
| Capital Expenditures (CapEx) | $90.0K | $153.0K |
| Free Cash Flow (FCF) | -$23.0M | -$20.2M |
| FCF Margin % | -80.0% | -80.0% |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% |
| Cash & Short-Term Equivalents | — | — |
| Total Debt (Short + Long Term) | — | — |
| Total Stockholders' Equity | $13.3M | -$129.5M |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR CV.